CEACAM5 and neoplasm: In a recent study, Cohen et al. [95] observed that the combination of testing circulating tumor DNA (ctDNA) with protein biomarkers (CA19-9, CEA, hepatocyte growth factor (HGF), and osteopontin) shows better performance than the CA19-9 test alone to distinguish PDAC from healthy controls.